# US 2019/0169272 A1 · Removal of serine proteases by treatment with finely divided silicon dioxide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2019/0169272 A1
- Document ID: US20190169272A1
- Status: Published application
- Kind: A1
- Application number: 16/241,551
- Filed: 2019-01-07
- Published: 2019-06-06
- Earliest claimed: 2010-05-26
- Assignees: Baxalta Incorporated
- Applicants: Baxalta Incorporated; Baxalta GmbH
- Inventors: Wolfgang Teschner; Hans-Peter Schwarz; Ruth Madlener; Sonja Svatos; Azra Pljevljakovic; Alfred Weber
- Web page: https://patentgrep.com/patent/US20190169272A1

## CPC

- C07K 16/065: {Purification, fragmentation}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/08: Solutions {(composition of solutions A61K47/00)}
- A61K 35/16: Blood plasma; Blood serum (umbilical cord blood A61K35/51)
- A61K 38/1709: {from mammals}
- A61K 39/39525: {Purification}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 31/00: Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P 37/00: Drugs for immunological or allergic disorders
- B01D 15/12: relating to the preparation of the feed
- B01D 15/122: {Solid phase extraction}
- B01D 15/362: {Cation-exchange}
- B01D 15/363: {Anion-exchange}
- B01D 15/424: {Elution mode}
- C07K 1/30: by precipitation
- C07K 1/36: by a combination of two or more processes of different types
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- B01D: SEPARATION (separating solids from solids by wet methods B03B, B03D; by pneumatic jigs or tables B03B; by other dry methods B07; magnetic or electrostatic separation of solid materials from solid materials or fluids, separation by high-voltage electric fields B03C; centrifuges, vortex apparatus B04; presses per se for squeezing-out liquid from liquid-containing material B30B9/02; treatment of water C02F, e.g. softening by ion-exchange C02F1/42; {arrangements of air intake cleaners in gas turbine plants F02C7/05} ; arrangements or mounting of filters in air-conditioning, air-humidification or ventilation F24F13/28)

## Abstract

The present invention provides novel methods for reducing the serine protease and/or serine protease zymogen content of a plasma-derived protein composition. Also provided are methods for manufacturing plasma-derived protein compositions having reduced serine protease and\or serine protease zymogen content. Among yet other aspects, the present invention provides aqueous and lyophilized compositions of plasma-derived proteins having reduced serine protease and/or serine protease zymogen content. Yet other aspects include methods for treating, managing, and/or preventing a disease comprising the administration of a plasma-derived protein composition having a reduced serine protease or serine protease zymogen content.

## Claims

### Claim at position 1

1-76. (canceled)

### Claim 77

A method for preparing an Immunoglobulin G (IgG) composition having a reduced amount of Factor XIa, the method comprising the steps of:
(a) precipitating a cryo-poor plasma fraction, in a first precipitation step, with from about 6% to about 10% alcohol at a pH of from about 7.0 to about 7.5 to obtain a first precipitate and a first supernatant;
(b) precipitating IgG from the first supernatant, in a second precipitation step, with from about 23% to about 27% alcohol at a pH of from about 6.7 to about 7.3 to form a second precipitate;
(c) suspending the second precipitate to form a first suspension;
(d) contacting the first suspension with fumed silica under a solution condition suitable to bind Factor XIa; and
(e) separating the fumed silica from the first suspension to form a clarified suspension, thereby forming an IgG composition having a reduced amount of Factor XIa.

### Claim 78 (depends on 77)

The method of claim 77, wherein the method further comprises the steps of:
(f) precipitating IgG from the clarified suspension formed in step (e), in a third precipitation step, with from about 22% to about 28% alcohol at a pH of from about 6.7 to about 7.3 to form a third precipitate;
(g) suspending the third precipitate to form a second suspension; and
(h) separating a soluble fraction from an insoluble fraction in the second suspension formed in step (g), thereby forming an enriched IgG composition.

### Claim 79 (depends on 77)

The method of claim 77, wherein the method further comprises an anion exchange chromatography enrichment step.

### Claim 80 (depends on 77)

The method of claim 77, wherein the method further comprises a cation exchange chromatography enrichment step.

### Claim 81 (depends on 77)

The method of claim 77, wherein the method further comprises at least one dedicated viral inactivation or removal step.

### Claim 82 (depends on 81)

The method of claim 81, wherein the method comprises a solvent/detergent (S/D) viral inactivation step.

### Claim 83 (depends on 81)

The method of claim 81, wherein the method comprises a nanofiltration step.

### Claim 84 (depends on 81)

The method of claim 81, wherein the method comprises an incubation step at low pH.

### Claim 85 (depends on 77)

The method of claim 77, wherein step (b) comprises adjusting the ethanol concentration of the first supernatant formed in step (a) to about 25% (v/v) at a temperature from about −7° C. to about −9° C.

### Claim 86 (depends on 85)

The method of claim 85, wherein step (b) is performed at a temperature of about −9° C.

### Claim 87 (depends on 78)

The method of claim 78, wherein step (c) comprises suspending the precipitate formed in step (b) with a buffer containing phosphate and acetate, wherein the pH of the buffer is adjusted with from 300 mL to 700 mL of glacial acetic acid per 1000 L of the buffer.

### Claim 88 (depends on 77)

The method of claim 77, wherein step (d) comprises the addition fumed silica to a final concentration of from about 0.02 grams per gram precipitate formed in step (b) to about 0.06 grams per gram precipitate formed in step (b).

### Claim 89 (depends on 77)

The method of claim 77, wherein the solution condition suitable to bind Factor XIa comprises a pH of from 4.5 to 6.0 and a conductivity of from 0.1 mS/cm to 3 mS/cm.

### Claim 90 (depends on 77)

The method of claim 77, wherein the first suspension is contacted with fumed silica at a pH of from 4.9 to 5.3.

### Claim 91 (depends on 90)

The method of claim 90, wherein the first suspension is contacted with fumed silica at a conductivity of from 0.5 mS/cm to 2 mS/cm.

### Claim 92

(canceled)

### Claim 93 (depends on 77)

The method of claim 77, further comprising the sub-step of:
(iv) treating the clarified suspension with a detergent.

### Claim 94

(canceled)

### Claim 95 (depends on 78)

The method of claim 78, wherein the enriched IgG composition obtained in step (h) contains at least 85% of the IgG content found in the cryo-poor plasma fraction used in step (a).

### Claim 96 (depends on 95)

The method of claim 95, wherein the enriched IgG composition obtained in step (h) contains at least 90% of the IgG content found in the cryo-poor plasma fraction used in step (a).

### Claim at position 22

97-115. (canceled)

### Claim 116 (depends on 77)

The method of claim 77, wherein step (b) comprises adjusting the ethanol concentration of the first supernatant formed in step (a) to about 25% (v/v) at a temperature from about −7° C. to about −9° C.

### Claim 117 (depends on 77)

The method of claim 77, wherein the first suspension is contacted with fumed silica at a pH of from 4.9 to 5.3 and a conductivity of from 0.5 mS/cm to 2 mS/cm.
